Real Healing. Real Change.

The Measure

A growing body of evidence demonstrates that psilocybin assisted therapy is uniquely effective and has an excellent safety track record. We think that this novel approach could help alleviate the mental health crisis here in Oregon by addressing epidemics like suicide, treatment-resistant depression and anxiety, PTSD, and addiction to drugs, alcohol, and nicotine. Additionally, the measure would open doors for new research and create access to services for those interested in personal development. ~ PSI Chief Petitioners Tom & Sheri Eckert

 

Measure 34 will legalize access to “psilocybin services” – also known as psilocybin assisted therapy – statewide.  Psilocybin, currently a Schedule 1 drug, would be administered in licensed therapeutic environments, supervised by trained facilitators. Rooted in research, the service model involves a sequence of sessions, including preparation, psilocybin administration, and integration afterwards. Each client will be screened for contraindications prior to scheduling a psilocybin session. Clients would not need a mental health diagnosis to qualify.

The measure envisions a community-based framework, where licensed providers, along with licensed producers of psilocybin mushrooms and products, legally operate in accordance with evolving standards.

The Oregon Health Authority (OHA) will oversee the program. The OHA’s first order of business will be to appoint and activate an independent Advisory Board of experts, representing a spectrum of disciplines ranging from science and medicine to public policy. With help from the Board, the OHA will issue rules and implement the measure’s regulations. Some primary duties of the OHA include issuing licenses and approving facilitator training programs, establishing practice and ethical standards, and implementing a system for tracking psilocybin products.

The oversight proposed in the measure emphasizes safety and harm reduction, with an ear to the scientific community. Public concerns are also at the fore – for example, the measure addresses the potential for diversion of psilocybin, ensures that no one will drive home altered, and prohibits service centers from operating in residential neighborhoods. Additionally, this legislation limits corporate influences and prohibits cannabis-style branding and marketing, favoring instead a circumscribed therapeutic frame.

   The measure imposes a two-year “development period” before issuing licenses. This gives the OHA time not only to prepare for implementation but also to educate the public about the program. The measure also directs the OHA to engage with state and federal officials during the development period, including the United States Attorney’s Office for the District of Oregon. The purpose of this outreach is to facilitate awareness of the program’s merits, so that it can unfold without legal entanglements.

Highlights of the Oregon Psilocybin Services Act of 2020

  • A framework for legally accessing psilocybin assisted therapy in Oregon
  • A science-based therapeutic modality including preparation, facilitation, and integration
  • Risk assessment for contraindications
  • Independent licenses for facilitators, service center operators, and producers of psilocybin mushrooms and products
  • Safety, practice, and ethical standards for trained and competent facilitators
  • No home use, no driving while altered, no retail psilocybin
  • No diagnosis required to receive psilocybin services
  • No big corporate incentives
  • Framework positioned outside of the conventional medical system
  • An advisory board of experts from relevant disciplines
  • Regulators cannot exclude mushrooms in favor of synthetic psilocybin
  • Transactions will not parallel the cannabis industry; no product branding and marketing
  • Limits on business entities – no big chains, no big manufacturers
  • Residency requirements for licensure, limits on outside money
  • An extended development period to protect successful roll out of the program